| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 2 |
吴国明，钱桂生. 应进一步加强对非小细胞肺癌靶向治疗的研究[J]. 中华医学杂志，2014, 94(30): 2321-2323.
|
| 3 |
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
|
| 4 |
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10): 947-957.
|
| 5 |
中华医学会呼吸病学分会肺癌学组. 晚期非小细胞肺癌分子靶向治疗专家共识(2013版) [J]. 中华结核和呼吸杂志，2014, 37: 177-183.
|
| 6 |
Rosell R, Dafni U, Felip E, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial[J]. Lancet Respir Med, 2017, 5(5): 435-444.
|
| 7 |
Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study[J]. Lancet Oncol, 2014, 15(11): 1236-1244.
|
| 8 |
Cheng Y, Murakami H, Yang PC, et al. Randomized phase Ⅱ trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations[J]. J Clin Oncol, 2016, 34(27): 3258-3266.
|
| 9 |
Nakamura A, Inoue A, Morita S, et al. Phase Ⅲ study comparing gefitinibmonotherapy (G) to combination therapy with gefitinib, carboplatin, andpemetrexed (GCP) for untreated patients (pts) with advanced nonsmall celllung cancer (NSCLC) with EGFR mutations (NEJ009) [J]. J Clin Oncol, 2018, 36: (suppl; abstr 9005)．
|
| 10 |
Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer[J]. N Engl J Med, 2017, 376(7): 629-640.
|
| 11 |
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 378(2): 113-125.
|
| 12 |
Cortinovis D1, Abbate M1, Bidoli P, et al. Targeted therapies and immunotherapy in non-small-cell lung cancer[J]. Ecancermedicalscience, 2016, 10: 648.
|
| 13 |
Thress KS, Paweletz CP, Felip E, et al. AcquiredEGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFRT790M[J]. Nat Med, 2015, 21(6): 560-562.
|
| 14 |
Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients[J]. Nat Commun, 2016, 7: 11815.
|
| 15 |
Wang Y, Li L, Han R, et al. Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib[J]. Lung Cancer, 2018, 118: 105-110.
|
| 16 |
Wang X, Zhou L, Yin JC, et al. Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy[J]. J Thorac Oncol, 2019, 14(5): e85-e88.
|
| 17 |
Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stageII-ⅢA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase3study[J]. Lancet Oncol, 2018, 19(1): 139-148.
|
| 18 |
Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stageⅢA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase2 trial[J]. Lancet Respir Med, 2018, 6(11): 863-873.
|
| 19 |
Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J]. N Engl J Med, 2014, 371(23): 2167-2177.
|
| 20 |
Crystal AS, Shaw AT, Sequist LV, et al. Patient-derivedmodels of acquired resistance can identify effectivedrug combinations for cancer[J]. Science, 2014, 346(6216): 1480-1486.
|
| 21 |
Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study[J]. Lancet, 2017, 389(10072): 917-929.
|
| 22 |
Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2017, 377(9): 829-838.
|
| 23 |
Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 379(21): 2027-2039.
|
| 24 |
Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models[J]．Cancer Cell, 2015, 28(1): 70-81.
|
| 25 |
Wang S, Yan B, Zhang Y, et al. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation[J]. Int J Cancer, 2019, 144(11): 2880-2886.
|
| 26 |
Duruisseaux M, Besse B, Cadranel J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study[J]. Oncotarget, 2017, 8(13): 21903-21917.
|